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Abstract  19	  
Fungal infections have dramatically increased in the last decades in parallel with an increase of 20	  
populations with impaired immunity, resulting from medical conditions such as cancer, 21	  
transplantation or other chronic diseases. Such opportunistic infections result from a complex 22	  
relationship between fungi and host, and can range from self-limiting to chronic or life-threatening 23	  
infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches 24	  
for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well 25	  
documented and associated with increased drug tolerance and resistance. In addition, biofilm 26	  
formation facilitates persistence in the host promoting a persistent inflammatory condition.  27	  
With a limited availability of antifungals within our arsenal, new therapeutic approaches able to 28	  
address both host and pathogenic factors that promote fungal disease progression, i.e. chronic 29	  
inflammation and biofilm-formation, could represent an advantage in the clinical setting.  30	  
In this paper we discuss the antifungal properties of Myriocin, Fulvic Acid and Acetylcholine in 31	  
light of their already known anti-inflammatory activity and as candidate dual action therapeutics to 32	  
treat opportunistic fungal infections. 33	  
 34	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Introduction  42	  
The population of subjects at risk of developing fungal infections is steadily increasing due to rising 43	  
life expectancy and the continuous medical progress in the treatment of serious diseases such as 44	  
cancer, transplantation or impairment of immune system (Brown et al., 2012). 45	  
Even though advanced medical treatments allow these patients to live longer, the exposure to 46	  
surgery and medical devices composed of polymeric materials results in evolved ecological niches 47	  
for biofilm-producing microorganisms and increases the risk for infectious diseases, including those 48	  
caused by opportunistic fungi (Ramage et al., 2006). Candida albicans amongst yeasts and 49	  
Aspergillus fumigatus amongst molds are still the most common pathogens in the clinical setting 50	  
(Guinea, 2014; Kriengkauykiat et al., 2011; Morace and Borghi, 2010), and continue to carry a high 51	  
mortality despite the antifungal treatment.  52	  
Antifungal resistance is emerging in Candida and Aspergillus species (Arendrup, 2014), and 53	  
together with intrinsic or acquired mechanisms, the drug tolerance related to biofilm formation is 54	  
emerging as having a crucial role in the failure of treatments (Ramage et al., 2014). Fungal cells 55	  
within the biofilms display resistance to azoles and polyenes, at least at therapeutic doses (Taff et 56	  
al., 2013). Echinocandins seem to achieve better results against Candida biofilms, but not against 57	  
Aspergillus fumigatus (Pierce et al., 2013). Thus, the development of new compounds able to 58	  
overcome the drug-resistance of biofilms is undoubtedly a current and, even more, a future medical 59	  
need for the treatment of such infections.  60	  
Recently, some compounds with known anti-inflammatory properties have been investigated for 61	  
their antifungal activity. This is of particular relevance in the context of fungal infections. The 62	  
interplay between fungus and host, i.e. immune system and inflammatory milieu, is crucial in 63	  
determining the tolerance or the disease status (Romani, 2011). Although inflammation is required 64	  
to control of fungal infections, its resolution is necessary to avoid collateral damage to tissues and 65	  
to restore a homeostatic environment (Romani, 2011). Drugs displaying dual activity, antifungal 66	  
and anti-inflammatory, could thus represent novel approaches to treat biofilm-related infections. In 67	  
this work we discuss the anti-biofilm properties of Myriocin, Fulvic Acid, and Acetylcholine, three 68	  
compounds recently investigated for their antifungal activity in the context of fungal biofilms. 69	  
 70	  
Myriocin  71	  
Sphingolipids (SPLs) are a class of molecules with structural and signaling activities conserved 72	  
from fungi to humans. Many studies have demonstrated that sphingolipid mediators are involved in 73	  
infection-related mechanisms (Mor et al., 2015). Both microbial and mammalian dysregulation of 74	  
SPLs play a role in the delicate relationship between pathogen and host during the infection 75	  
process, having an impact on signaling pathways that eventually lead to commensalism or host 76	  
damage (Heung et al., 2006). 77	  
Fungal SLPs have been implicated in several cellular processes such as endocytosis, apoptosis, heat 78	  
stress response, and fungal pathogenesis (Lattif et al., 2011). In fact, SLPs are part, together with 79	  
ergosterol, of plasma membrane domains named lipid rafts that are crucial for cell signaling and 80	  
membrane trafficking, and mediate protein-protein interactions (Farnoud et al., 2015).  81	  
Changes in the SPLs content could thus strongly impact the local membrane structure and alter 82	  
specific protein localization such as the GPI-anchored proteins (Singh and Del Poeta, 2011). These 83	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have been extensively studied in C. albicans and are crucial for adhesion to substrates in the early 84	  
phases of biofilm-formation (Cabral et al., 2014). Differences in SPLs content have been observed 85	  
in planktonic and sessile cells of C. albicans, suggesting a role for the lipid moiety in biofilm-86	  
formation and maturation (Lattif et al., 2011). Lipid rafts have been found to localize at the hyphal 87	  
tip, and drugs affecting SLPs biosynthesis, such as Myriocin, lead to defects in hypha formation 88	  
(Martin and Konopka, 2004).  89	  
Myriocin targets the first step of SPLs de novo biosynthesis, by inhibiting the enzyme serine 90	  
palmitoyl transferase (SPT) that catalyzes the condensation of a fatty acyl CoA with serine, a 91	  
common step to both fungal and mammalian SLPs biosynthesis.  92	  
Many cell-stress responses cause ceramide, the central molecule of SLP metabolism, to accumulate 93	  
and trigger the activation of inflammatory processes (Hannun and Obeid, 2008). High levels of 94	  
ceramide are characteristic of several inflammatory diseases. Animal models showed that Myriocin 95	  
treatment is able to reduce inflammation by down-regulating ceramide and its related pro-96	  
inflammatory cascade (Jiang et al., 2012; Caretti et al., 2014; Lee et al., 2012). 97	  
Besides this action and similarly to other SPLs metabolism inhibitors (Groll et al., 1998; Mormeneo 98	  
et al., 2008), Myriocin has a direct antifungal activity (Martin and Konopka, 2004; Lattif et al., 99	  
2011; de Melo et al., 2013; Sharma et al., 2014). Recently, Lattif and coworkers assessed a potential 100	  
antibiofilm activity for the drug. The authors grew C. albicans biofilms in the presence and absence 101	  
of various Myriocin concentrations and observed a progressive reduction in biofilm biomass and 102	  
metabolic activity. In addition, lipid raft formation was strongly reduced as well as the C. albicans 103	  
filamentation (Lattif et al., 2011). 104	  
Myriocin has been found to be also active against A. fumigatus (Cirasola et al., 2014). 105	  
Administration of Myriocin to conidia resulted in a dose-dependent inhibition of germination, 106	  
whereas the treatment of 24h pre-formed biofilms strongly reduced the biofilm biomass, as 107	  
determined by crystal violet assay, and the metabolic activity. In particular, Myriocin led to the 108	  
presence of aberrant hyphal structures in A. fumigatus, with increased branching and reduction in 109	  
apical hyphal growth. Hyphal polarization and branching in A. fumigatus, as well as filamentation 110	  
in C. albicans, have been shown to be crucial for virulence and biofilm formation, resulting in more 111	  
stable biofilms (Riquelme, 2013; Brand, 2012). The inhibition of sphingolipid metabolism disrupts 112	  
the actin organization at the tip, impacting on normal hyphal growth and differentiation (Cheng et 113	  
al., 2001). Moreover, a deprived quantity of SLPs results in a decrease of sphingolipids in lipid rafts 114	  
with a subsequent reduction of plasma membrane-anchored proteins that participate in the 115	  
maintenance of polarized growth (Momany, 2002). Although the compound is also active against 116	  
planktonic fungal cells, all the major SLPs classes seem to be over-represented in the biofilm-117	  
organized cells (Lattif et al., 2011), suggesting a key role for SLPs in modulating biofilm formation. 118	  
To improve the delivery of Myriocin, a highly lipophilic compound, Strettoi and colleagues (2011) 119	  
explored the use of solid lipid nanocarriers in a mice model of retinitis pigmentosa. Similarly, other 120	  
authors observed a decrease in the effective drug concentration compared with pure compound 121	  
when using nanocarrier delivery in a cystic fibrosis mouse model (Caretti et al, 2014). By treating 122	  
mice with intratrachea myriocin-loaded nanocarriers, Caretti and colleague were able to achieve a 123	  
reduction of lung infection and inflammation after Pseudomonas aeruginosa infection.  124	  
Due to the poor penetration of biofilm matrix by drugs, the same nanocarriers were investigated on 125	  
fungal biofilms. Nanocarriers improved Myriocin delivery into A. fumigatus biofilms, allowing its 126	  
distribution within few hours even in bottom layers (Cirasola et al., 2014). 127	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Due to its dual action, anti-inflammatory and antifungal, Myriocin might represent a useful 128	  
treatment for patients suffering from chronic diseases that increase the risk of fungal infections. 129	  
However, deeper investigations into its administration need to be performed. Recently de Melo and 130	  
coworkers (2013) observed that prophylaxis treatment with Myriocin, in an invertebrate model of 131	  
systemic candidiasis, reduces the insect survival (de Melo et al., 2013). The optimal scenario for the 132	  
Myriocin use could be late phases of fungal infection as well as pathological situations 133	  
characterized by ceramide mediated hyper-inflammation. On the other hand, the development of 134	  
Myriocin derivatives as well as other compounds targeting downstream steps in the fungal SLP 135	  
synthesis could increase the specificity of these compounds against fungal enzymes avoiding host 136	  
side effects. 137	  
 138	  
Fulvic acid  139	  
Humic substances are commonly found in decaying organic matter including plants, animal 140	  
residues, sewage and soil (Snyman et al., 2002). Although fulvic acids account for ~90% of all 141	  
humic substances and their biological significance recognized for many years (van Rensburg et al., 142	  
2000), there is still minimal scientific understanding on which to support the claims of its biological 143	  
properties. Oxifulvic acid, a derivate of fulvic acid, has been shown to elicit antibacterial and 144	  
antifungal properties (van Rensburg et al., 2000). However, these formulations contain numerous 145	  
toxic elements that make their use clinically impossible. Recently, there has been the development 146	  
of a pure form of fulvic acid, carbohydrate derived fulvic acid (CHD-FA), that has been shown to 147	  
be safe to use clinically and absent from environmental contaminants known to be harmful to the 148	  
host (Gandy et al., 2011).  149	  
An initial randomized double blind controlled trial indicated that fulvic acid was well-tolerated in 150	  
patients with eczema, where side effects were minimal and severity and erythema were significantly 151	  
reduced compared with the placebo control (Gandy et al., 2011). A subsequent phase 1 clinical 152	  
study carried out to determine the safety profile of CHD-FA, showed that this agent was able to 153	  
elicit anti-inflammatory properties in addition to being non-toxic when used as an oral formulation 154	  
(Gandy et al., 2012). This anti-inflammatory activity was also shown in a rat wound model, where 155	  
the use of a topical cream enhanced wound healing and was non-toxic during both acute and 156	  
chronic treatments (Sabi et al., 2012). However, so far the mechanism by which CHD-FA elicits the 157	  
observed immunomodulatory effects is unknown. 158	  
Although the anti-inflammatory properties of CHD-FA have been studied, there are very few 159	  
reports of the antimicrobial properties of this agent. Recent studies have shown CHD-FA to be 160	  
fungicidal against C. albicans planktonic and sessile cells at similar concentrations, indicating good 161	  
biofilm activity unlike azole antifungals (Sherry et al., 2012). Time-kill analysis of CHD-FA was 162	  
performed in comparison to the other classes of antifungals, and whilst caspofungin achieved the 163	  
greatest kill, CHD-FA elicited its maximum activity quicker than any of the other agents, which is 164	  
of particular benefit in treating systemic infections such as candidemia, where delayed antifungal 165	  
therapy coincides with mortality rates (Morrell et al., 2005). The rapid killing action was further 166	  
analyzed by visualizing the uptake of propidium iodide by the cells, only feasible when the cell 167	  
membrane has been compromised. Membrane damage was recorded as early as 10 min following 168	  
CHD-FA exposure, which also correlates with the release of intracellular ATP from the cell (Sherry 169	  
et al., 2012).  To further test the hypothesis of a membrane active compound, the activity against the 170	  
C. albicans cell membrane was investigated using a chitin synthase inhibitor. Chitin is a simple 171	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polysaccharide found in the cell walls of fungi that provides cell structure and rigidity (Lenardon et 172	  
al., 2010). It was argued that if the cell membrane was the target of CHD-FA, then by weakening 173	  
the cell by inhibiting its chitin production would increase the exposure of the cell membrane to the 174	  
agent and would increase CHD-FA sensitivity (Sherry et al., 2012). Here it was demonstrated that 175	  
C. albicans cells were hyper-susceptible to CHD-FA in the presence of a chitin synthase inhibitor, a 176	  
finding that was also observed in voriconazole treated biofilms (Kaneko et al., 2010). Collectively, 177	  
these data suggest that CHD-FA acts through disruption to the cell membrane. It is therefore 178	  
feasible to suggest that this agent may have broad-spectrum antimicrobial activity against a variety 179	  
of fungi and bacteria. Indeed, this was the case when CHD-FA was shown to possess antibacterial 180	  
activity towards a range of oral bacterial biofilms, including an in vitro four-species periodontal 181	  
biofilm model (Sherry et al., 2013).  182	  
Additionally, fulvic acid was shown to be minimally affected by characterized biofilm resistance 183	  
mechanisms, including the extracellular matrix (ECM) and efflux pumps. For example, it is known 184	  
that glucans within the cellular matrix hinder the penetration of azoles through biofilms, with the 185	  
depletion of FKS1, encoding a β-1,3 glucan synthase, increasing the susceptibility of fluconazole 186	  
within these communities (Nett et al., 2010a, Nett et al., 2010b). Overexpression of FKS1, as well 187	  
as a deletion mutant, was used to determine the impact of CHD-FA activity. Here it was shown that 188	  
this agent’s sensitivity was not compromised by the elevated expression of FKS1, which is in 189	  
contrast to azoles, polyenes and echinocandins, where the matrix sequesters these agents and their 190	  
activity is significantly reduced against C. albicans biofilms (Nett et al., 2010a).  191	  
Efflux pumps have been widely shown to play a role in azole resistance within Candida biofilms, 192	  
particularly during early biofilm development both in vitro and in vivo (Mukherjee et al., 2003, Nett 193	  
et al., 2009, Ramage et al., 2002). Although CHD-FA was shown to induce efflux pump activity in 194	  
C. albicans biofilms, there was no change in the minimum inhibitory concentration (MIC) when an 195	  
efflux pump inhibitor was used, demonstrating that CHD-FA activity is not compromised by these 196	  
pumps unlike other antifungals (Sherry et al., 2012).  197	  
Overall, whilst our knowledge base for CHD-FA is relatively limited, it does appear to have 198	  
appropriate biological properties of a broad-spectrum antimicrobial agent and not compromised by 199	  
know biofilm resistance mechanisms, which has yet undefined immunomodulatory capacity. 200	  
Further in vitro and in vivo studies are required to determine its safety profile.  201	  
 202	  
Acetylcholine  203	  
Bi-directional neurochemical interactions occur between the host and colonizing microorganisms 204	  
(Lyte, 2013, 2014a and 2014b; Sandrini et a., 2015). Many microorganisms share neuro-endocrine 205	  
mediator synthesis pathways and recognition receptors with their human hosts (Lyte, 2013). 206	  
Therefore, it is hypothesized that there is constant communication between a vertebrate host and its 207	  
microbiota, and a bi-directional influence on behavior (Freestone, 2013). However, many of the 208	  
inter-kingdom signaling molecules and receptors, particularly from the fungal perspective, remain 209	  
to be characterized in detail. Furthermore, the biological consequences of neuro-endocrine signaling 210	  
in fungi, with respect to growth and pathogenicity, are only just beginning to be determined.  211	  
Acetylcholine (ACh) is widely distributed in both prokaryotic and eukaryotic cells. In mammalian 212	  
systems, ACh has two major roles: (1) neuronal ACh acts as a neurotransmitter to mediate rapid 213	  
communication between neurons and effector cells and (2) non-neuronal ACh acts as a local 214	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signaling molecule involved in the regulation of cellular phenotype, modification of ciliary activity, 215	  
and modification of cell-cell contact (Wessier and Kirkpatrick, 2008). In recent years ACh has 216	  
received greater attention due to the discovery of the ‘cholinergic anti-inflammatory pathway’ that 217	  
has been demonstrated to regulate immune responses (Borovikova et al., 2000). In this pathway, 218	  
ACh released from efferent vagus nerve terminals interacts with the alpha 7 nicotinic receptor 219	  
(α7nAChR) on proximal immune cells resulting in down regulated localized immune responses. In 220	  
addition, the efferent vagus nerve interacts with the splenic nerve to activate a unique ACh-221	  
producing memory phenotype T-cell population, which can propagate ACh mediated immune-222	  
regulation throughout the body (Rosas-Ballina et al., 2011). Furthermore, as ACh is also produced 223	  
by cells out with neural networks, non-neuronal ACh can also play a vital role in localized immune-224	  
regulation through its cytotransmitter capabilities (de Jonge et al., 2005; Macpherson et al., 2014). 225	  
In addition, evidence also suggests that ACh signaling through other cholinergic receptor subtypes, 226	  
such as the muscarinic receptors, can also modulate inflammatory responses in mammalian systems 227	  
(Verbout and Jacoby 2012).   228	  
Interestingly, in a recent study, ACh was found to play multiple roles in the pathogenesis of fungal 229	  
infections in a primitive Galleria mellonella infection model. Specifically, ACh was found to: (i) 230	  
inhibit C. albicans yeast–to-hyphae transition and biofilm formation; (ii) promote a rapid and 231	  
effective cellular immune response to C. albicans infection, and (iii) regulate antifungal defenses to 232	  
limit sepsis induced damage of host tissues (Rajendran et al., 2015). The fact that ACh can directly 233	  
act on C. albicans to inhibit yeast–to-hyphae transition suggests that this organism possesses a 234	  
functional ACh receptor.  However, the ACh receptor(s) and the downstream signaling pathway(s) 235	  
that are involved in inhibiting C. albicans yeast–to-hyphae transition have yet to be characterized in 236	  
detail.  237	  
Sequencing of the C. albicans genome has suggested this organism possesses putative cholinergic 238	  
receptor genes (Inglis et al., 2012). Furthermore, pharmacological evidence suggests that C. 239	  
albicans may possess a receptor that is homologous to human muscarinic (M) receptors. Midkiff et 240	  
al (2011) demonstrated that the dopamine receptor antagonist clozapine could inhibit C. albicans 241	  
budding-to-hyphal transition by inhibiting a component of the Efg1 pathway, upstream of the Gpa2 242	  
G-alpha subunit, which the authors hypothesized to be the Gpr1 G-protein-coupled receptor 243	  
(GPCR). However, clozapine has a broad range complex pharmacological profile. Indeed, it is now 244	  
known that clozapine is a weak dopamine D2 receptor inverse agonist/antagonist and has mixed 245	  
agonist-antagonist properties on human muscarinic receptors, with strong evidence that it can act as 246	  
a potent agonist of the M1 and M4 receptors in mammalian systems (Olianas et al., 1999; 247	  
Wiebelhaus et al., 2012; Olianas et al., 1997; Zorn et al., 1994; Miller, 2009). Therefore, it is 248	  
interesting to speculate that the observed effects on C. albicans budded-to-hyphal transition in the 249	  
study of Midkiff et al (2011) may be in fact due to clozapine acting upon a putative C. albicans 250	  
cholinergic receptor homologous to human muscarinic receptors. However, further research aimed 251	  
at characterizing the cholinergic receptor mediated signaling pathways of C. albicans is required to 252	  
confirm this hypothesis. 253	  
There is also substantial evidence to suggest that fungi can synthesize and release ACh  (Horiuchi et 254	  
al., 2003; Kawashima and Fujii, 2008). Indeed, sequencing of the C. albicans genome revealed this 255	  
organism to possess putative genes for the enzymes responsible for ACh synthesis; choline 256	  
acetyltransferase (ChAT) and carnitine acetyltransferase (CrAT) (Inglis et al., 2012). However, the 257	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ACh synthesis machinery of C. albicans remains to be characterized. Furthermore, the biological 258	  
functions of fungal derived ACh remain to be elucidated.  259	  
The fact that both C. albicans and its human host both synthesize ACh and possess cholinergic 260	  
receptors lead to speculate that there is cholinergic mediated bi-directional communication between 261	  
the two species in vivo. The role of this cholinergic bi-directional communication in the 262	  
maintenance of health and/or the pathogenesis of C. albicans infections are at present unknown. 263	  
The evidence to date suggests the host may utilize ACh to protect against candidiasis (Rajendran et 264	  
al., 2015). Although, the fact that ACh can modulate host immunity (Tracey, 2010) and also 265	  
mucosal integrity through the regulation of epithelial cell phenotype and cell-cell contact (Wessler 266	  
and Kirkpatrick, 2008), may also suggest that C. albicans derived ACh may be a potential virulence 267	  
factor. Either way, further research into the role of bi-directional cholinergic signaling mechanisms 268	  
between C. albicans and the colonized host is required.  269	  
The preliminary data to date imply that cholinergic mechanisms may be rational novel therapeutic 270	  
targets to prevent or treat candidiasis (Rajendran et al., 2015). Indeed, there are a number of 271	  
pharmacological agonists and antagonists already marketed for the treatment of neurodegenerative 272	  
disorders, cancers and chronic inflammatory diseases that target cholinergic receptors (Sales, 2013; 273	  
Russo et al., 2014; Matera and Tata, 2014; Zoheir et al., 2012; Pohanka, 2012). Many of these 274	  
molecules have already undergone extensive safety and efficacy testing in human trials. Therefore, 275	  
one or more of these molecules may be worthy of investigation for the prevention or treatment of 276	  
candidiasis and may offer novel therapeutic approaches beyond conventional antifungals. 277	  
 278	  
Concluding Remarks  279	  
The opportunistic nature of fungal infections highlights the crucial role of the host immune system 280	  
in regulating host-fungus interactions. 281	  
Humans suffer from a range of fungal biofilm diseases that cause high levels of morbidity and 282	  
mortality. Conventional antifungal drugs have been demonstrated to ineffective against fungal 283	  
biofilms, and alternative strategies are needed to overcome their intrinsic resistance.  284	  
Therefore molecules targeting both fungal biofilm formation and the host inflammatory response 285	  
could represent a new therapeutic approach to treat fungal biofilm-related infections with broader 286	  
implications for healthcare applications. 287	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